scholarly journals Systemic Inflammatory Response in Pancreatic Ductal Adenocarcinoma

2018 ◽  
Author(s):  
Arturs Silovs ◽  
Ilze Strumfa ◽  
Reinis Riekstins ◽  
Zane Simtniece ◽  
Andrejs Vanags ◽  
...  
Keyword(s):  
Inflammatory Response ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Systemic Inflammatory Response ◽  
Ductal Adenocarcinoma

scholarly journals Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma

PLoS ONE ◽  
2016 ◽  
Vol 11 (9) ◽  
pp. e0163064 ◽  
Author(s):  
Aino Salmiheimo ◽  
Harri Mustonen ◽  
Ulf-Håkan Stenman ◽  
Pauli Puolakkainen ◽  
Esko Kemppainen ◽  
...  
Keyword(s):  
Inflammatory Response ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Systemic Inflammatory Response ◽  
Tumour Markers ◽  
Ductal Adenocarcinoma

scholarly journals The effects of systemic inflammatory response on prognosis of pancreatic ductal adenocarcinoma

2019 ◽  
Vol 23 (2) ◽  
pp. 155
Author(s):  
Ali Aktekin ◽  
Mehmet Torun ◽  
Bala Basak Oven Ustaalioğlu ◽  
Selvinaz Ozkara ◽  
Ozcan Cakır ◽  
...  
Keyword(s):  
Inflammatory Response ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Systemic Inflammatory Response ◽  
Ductal Adenocarcinoma

Systemic inflammatory response and elevated tumour markers predict worse survival in pancreatic ductal adenocarcinoma

Pancreatology ◽  
2016 ◽  
Vol 16 (3) ◽  
pp. S40
Author(s):  
Aino Salmiheimo ◽  
Harri Mustonen ◽  
Ulf-Hĺkan Stenman ◽  
Pauli Puolakkainen ◽  
Esko Kemppainen ◽  
...  
Keyword(s):  
Inflammatory Response ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Systemic Inflammatory Response ◽  
Tumour Markers ◽  
Ductal Adenocarcinoma

Predictive factors in pancreatic ductal adenocarcinoma: Role of the inflammatory response

2007 ◽  
Vol 42 (6) ◽  
pp. 754-759 ◽  
Author(s):  
Bobby Tingstedt ◽  
Patrik Johansson ◽  
Bodil Andersson ◽  
Roland Andersson
Keyword(s):  
Inflammatory Response ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Predictive Factors ◽  
Ductal Adenocarcinoma

scholarly journals Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas

2004 ◽  
Vol 92 (1) ◽  
pp. 21-23 ◽  
Author(s):  
N B Jamieson ◽  
P Glen ◽  
D C McMillan ◽  
C J McKay ◽  
A K Foulis ◽  
...  
Keyword(s):  
Inflammatory Response ◽  
Systemic Inflammatory Response ◽  
Ductal Adenocarcinoma ◽  
Head Of Pancreas

scholarly journals An Inflammatory Response Related Gene Signature Associated with Survival Outcome and Gemcitabine Response in Patients with Pancreatic Ductal Adenocarcinoma

2021 ◽  
Vol 12 ◽  
Author(s):  
Zhijun Xiao ◽  
Jinyin Li ◽  
Qian Yu ◽  
Ting Zhou ◽  
Jingjing Duan ◽  
...  
Keyword(s):  
High Risk ◽  
Inflammatory Response ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Risk Score ◽  
Risk Group ◽  
Expression Profiles ◽  
Ductal Adenocarcinoma ◽  
Prognostic Signature ◽  
Characteristic Analysis ◽  
Local Immunosuppression

Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive tumors with an extremely low 5-year survival rate. Accumulating evidence has unveiled that inflammatory response promotes tumor progression, enhances angiogenesis, and causes local immunosuppression. Herein, we aim to develop an inflammatory related prognostic signature, and found it could be used to predict gemcitabine response in PDAC.Methods: PDAC cohorts with mRNA expression profiles and clinical information were systematically collected from the four public databases. An inflammatory response related genes (IRRGs) prognostic signature was constructed by LASSO regression analysis. Kaplan–Meier survival analysis, receiver operating characteristic analysis, principal component analysis, and univariate and multivariate Cox analyses were carried out to evaluate effectiveness, and reliability of the signature. The correlation between gemcitabine response and risk score was evaluated in the TCGA-PAAD cohort. The GDSC database, pRRophetic algorithm, and connectivity map analysis were used to predict gemcitabine sensitivity and identify potential drugs for the treatment of PDAC. Finally, we analyzed differences in frequencies of gene mutations, infiltration of immune cells, as well as biological functions between different subgroups divided by the prognostic signature.Results: We established a seven IRRGs (ADM, DCBLD2, EREG, ITGA5, MIF, TREM1, and BTG2) signature which divided the PDAC patients into low- and high-risk groups. Prognostic value of the signature was validated in 11 PDAC cohorts consisting of 1337 PDAC patients from 6 countries. A nomogram that integrated the IRRGs signature and clinicopathologic factors of PDAC patients was constructed. The risk score showed positive correlation with gemcitabine resistance. Two drugs (BMS-536924 and dasatinib) might have potential therapeutic implications in high-risk PDAC patients. We found that the high-risk group had higher frequencies of KRAS, TP53, and CDKN2A mutations, increased infiltration of macrophages M0, neutrophils, and macrophages M2 cells, as well as upregulated hypoxia and glycolysis pathways, while the low-risk group had increased infiltration of CD8+ T, naïve B, and plasma and macrophages M1 cells.Conclusion: We constructed and validated an IRRGs signature that could be used to predict the prognosis and gemcitabine response of patients with PDAC, as well as two drugs (BMS-536924 and dasatinib) may contribute to PDAC treatment.

Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma

2000 ◽  
Vol 15 (11) ◽  
pp. 1333-1338 ◽  
Author(s):  
Koji Uno ◽  
Takeshi Azuma ◽  
Masatsugu Nakajima ◽  
Kenjiro Yasuda ◽  
Takanobu Hayakumo ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Clinical Significance ◽  
Pancreatic Juice ◽  
Ductal Adenocarcinoma ◽  
Cathepsin E
Sign in / Sign up

Export Citation Format

Share Document